APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:14:42-05:00August 11, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RELEASES ENVIRONMENTAL, SOCIAL AND GOVERNANCE DATA IN NEW TEAR SHEETBy ApyxMedical|2025-12-12T19:15:08-05:00July 27, 2022|2022 Shareholder News, J-Plasma, Renuvion|
RENUVION CLEARED BY FDA FOR NECK LAXITY PROCEDURES OFFERING PATIENTS A MINIMALLY INVASIVE OPTION TO ELIMINATE SAGGING NECKBy ApyxMedical|2025-12-12T19:15:31-05:00July 18, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKINBy ApyxMedical|2025-12-12T19:15:55-05:00July 18, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES RESULTS OF THE U.S. IDE CLINICAL STUDY EVALUATING THE USE OF RENUVION TO IMPROVE THE APPEARANCE OF LAX SKIN IN THE NECK AND SUBMENTAL REGIONBy ApyxMedical|2025-12-12T19:16:26-05:00July 8, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON AUGUST 11, 2022By ApyxMedical|2025-12-12T19:16:50-05:00June 30, 2022|2022 Shareholder News, J-Plasma, Renuvion|
RENUVION DERMAL HANDPIECE FOR WRINKLE-REDUCTION PROCEDURES CLEARED BY FDABy ApyxMedical|2025-12-12T19:17:12-05:00June 28, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION COSMETIC TECHNOLOGY IN DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:17:54-05:00May 26, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNEBy ApyxMedical|2025-12-12T19:18:17-05:00May 25, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:18:44-05:00May 12, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON MAY 12, 2022By ApyxMedical|2025-12-12T19:19:07-05:00April 4, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION WITH CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION APR HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX SKINBy ApyxMedical|2025-12-12T19:19:32-05:00April 4, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:20:04-05:00March 17, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION NOTIFIED OF PENDING FDA MEDICAL DEVICE SAFETY COMMUNICATION RELATED TO ITS ADVANCED ENERGY PRODUCTSBy ApyxMedical|2025-12-12T19:20:29-05:00March 14, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED PUBLICATION FEATURING RESULTS FROM THE U.S. IDE CLINICAL STUDY EVALUATING THE RENUVION DERMAL HANDPIECE USING APYX’S HELIUM PLASMA TECHNOLOGY FOR DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:27:53-05:00February 17, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 17, 2022By ApyxMedical|2025-12-12T19:21:22-05:00January 27, 2022|2022 Shareholder News, J-Plasma, Renuvion|
